Impedance cardiography (ICG) is a noninvasive technology measuring total electrical conductivity of the thorax and its changes over time. The technology continuously processes a number of cardiodynamic parameters, such as Stroke Volume (SV), Heart Rate (HR), Cardiac Output (CO), Ventricular Ejection Time (VET), and Pre-ejection Period.
Electrical cardiometry is similar to impedance cardiography in the fact that both methods measure thoracic electrical bioimpedance (TEB). The methods differ from what phenomenon is responsible for the steep increase in TEB per heartbeat.
Outpatient cardiac hemodynamic monitoring devices are intended to improve quality of life and reduce hospitalizations as well as morbidity for patients with heart failure by decreasing episodes of acute decompensation.
These monitoring devices were developed to identify physiologic changes that precede clinical symptoms and, therefore, allow for early intervention to prevent decompensation and hospitalizations.
In the ambulatory care and outpatient settings, cardiac hemodynamic monitoring devices for the management of heart failure utilizing thoracic bioimpedance, inert gas rebreathing, arterial pressure during Valsalva maneuver, and implantable direct pressure monitoring of the pulmonary artery are considered experimental/investigational and, therefore, non-covered.
Scientific evidence has not shown that those technologies improve patient outcomes, nor have the data shown long term effectiveness or safety.
Noninvasive Thoracic Impedance Plethysmography Device
Noninvasive Left Ventricular End Diastolic Pressure (LVEDP) Measurement Devices
Implantable Pulmonary Artery Pressure Measurement Devices
Inert Gas Rebreathing Device